Literature DB >> 17555945

In vitro activity of voriconazole against dermatophytes, Scopulariopsis brevicaulis and other opportunistic fungi as agents of onychomycosis.

A J Carrillo-Muñoz1, G Giusiano, J Guarro, G Quindós, C Guardia, O del Valle, V Rodríguez, D Estivill, C D Cárdenes.   

Abstract

Using a reference microdilution method, we studied the antifungal susceptibility to voriconazole and fluconazole of 304 clinical isolates from four species of onychomycosis-causing dermatophytes, 196 isolates of dermatophytes not related to nail infection as well as Scopulariopsis brevicaulis, Fusarium spp. and Scytalidium dimidiatum. Results showed a high antifungal activity of voriconazole against dermatophytes (geometric mean minimal inhibitory concentration (MIC)=1.14 microg/mL; MIC for 50% of the organisms (MIC(50))=0.062 miccrog/mL; MIC for 90% of the organisms (MIC(90))=0.25 microg/mL). For S. brevicaulis, the in vitro activity of voriconazole was considerably lower (geometric mean MIC=8.52 microg/mL; MIC(50) and MIC(90)=16 microg/mL). Although voriconazole is not among the drugs recommended for the management of onychomycosis, it can be a useful alternative for recalcitrant infections.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17555945     DOI: 10.1016/j.ijantimicag.2007.04.004

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  8 in total

1.  Scopulariopsis, a poorly known opportunistic fungus: spectrum of species in clinical samples and in vitro responses to antifungal drugs.

Authors:  Marcelo Sandoval-Denis; Deanna A Sutton; Annette W Fothergill; Josep Cano-Lira; Josepa Gené; C A Decock; G S de Hoog; Josep Guarro
Journal:  J Clin Microbiol       Date:  2013-09-11       Impact factor: 5.948

2.  [New apects in the diagnosis and therapy of dermatomycoses].

Authors:  J Brasch
Journal:  Hautarzt       Date:  2012-05       Impact factor: 0.751

3.  Comparison of the in vitro activities of newer triazoles and established antifungal agents against Trichophyton rubrum.

Authors:  Shuwen Deng; Chao Zhang; Seyedmojtaba Seyedmousavi; Shuang Zhu; Xin Tan; Yiyang Wen; Xin Huang; Wenzhi Lei; Zhaojing Zhou; Wenjie Fang; Shuaishuai Shen; Danqi Deng; Weihua Pan; Wanqing Liao
Journal:  Antimicrob Agents Chemother       Date:  2015-04-20       Impact factor: 5.191

4.  In vitro activities of a wide panel of antifungal drugs against various Scopulariopsis and Microascus species.

Authors:  Magdalena Skóra; Małgorzata Bulanda; Tomasz Jagielski
Journal:  Antimicrob Agents Chemother       Date:  2015-06-22       Impact factor: 5.191

Review 5.  Successful Treatment of Refractory Majocchi's Granuloma with Voriconazole and Review of Published Literature.

Authors:  H B Liu; F Liu; Q T Kong; Y N Shen; G X Lv; W D Liu; H Sang
Journal:  Mycopathologia       Date:  2015-06-05       Impact factor: 2.574

6.  Investigation of In Vitro Activity of Five Antifungal Drugs against Dermatophytes Species Isolated from Clinical Samples Using the E-Test Method.

Authors:  Ayse Esin Aktas; Nimet Yigit; Akin Aktas; Sultan Gamze Gozubuyuk
Journal:  Eurasian J Med       Date:  2014-02

7.  In Vitro Antifungal Susceptibility Profiles of 12 Antifungal Drugs against 55 Trichophyton schoenleinii Isolates from Tinea Capitis Favosa Patients in Iran, Turkey, and China.

Authors:  Shuwen Deng; Saham Ansari; Macit Ilkit; Haleh Rafati; Mohammad T Hedayati; Mojtaba Taghizadeh-Armaki; Ayatollah Nasrollahi-Omran; Ali Tolooe; Ping Zhan; Wanqing Liao; Henrich A van der Lee; Paul E Verweij; Seyedmojtaba Seyedmousavi
Journal:  Antimicrob Agents Chemother       Date:  2017-01-24       Impact factor: 5.191

8.  In-vitro Activity of 10 Antifungal Agents against 320 Dermatophyte Strains Using Microdilution Method in Tehran.

Authors:  Parvaneh Adimi; Seyed Jamal Hashemi; Mahmood Mahmoudi; Hossein Mirhendi; Mohammad Reza Shidfar; Masood Emmami; Ali Rezaei-Matehkolaei; Mohsen Gramishoar; Parivash Kordbacheh
Journal:  Iran J Pharm Res       Date:  2013       Impact factor: 1.696

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.